Evidence map›Paper›PMID 41439791›Full record

ArticleJournal of medical virology2026

Loop-Mediated Isothermal Amplification Enables Reliable Kaposi Sarcoma Diagnosis Across Time and Sites in East Africa.

Xinying Chu, Jason C Manning, Juan M Boza, Miranda Mcgaskey, Racheal Ayanga, Hilda Muwando, Megan Wenger, Robert Lukande, Toby Maurer, Ethel Cesarman and 3 more

Abstract read
In one paragraph

Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xinying ChuSibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, New York, USA.ORCID https://orcid.org/0000-0003-1706-7642
Jason C ManningMeinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Juan M BozaMeinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Miranda McgaskeyDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
Racheal AyangaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Hilda MuwandoInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Megan WengerDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Robert LukandeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Toby MaurerDepartment of Dermatology, Indiana University, Bloomington, Indiana, USA.
Ethel CesarmanDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
Jeffrey MartinDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Aggrey SemeereInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
David EricksonSibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, New York, USA.

Funding

Technology CoreU54EB034654 · NIBIB · CORNELL UNIVERSITY · PI David Carl Erickson · 2023 to 2026
$7.0M
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETEU01CA269199 · NCI · CORNELL UNIVERSITY · PI Ethel Cesarman, David Carl Erickson · 2022 to 2026
$3.0M
NCI NIH HHS U01 CA269199NIBIB NIH HHS U54 EB034654
6 · The paper itself

Abstract

Kaposi sarcoma (KS) is an endothelial cancer caused by the Kaposi sarcoma-associated herpesvirus (KSHV), and it remains one of the most frequently diagnosed and fatal cancers in sub-Saharan Africa. Achieving timely and accurate diagnosis for KS is a critical challenge in sub-Saharan Africa, where access to histopathology is limited and clinical diagnosis is often erroneous. Previously, a point-of-care device was developed to quantify KSHV DNA and demonstrated promising performance, achieving 97% sensitivity and 92% specificity at a 26-min threshold in a training set of patients from several Ugandan clinics. Herein, 421 skin biopsies from a different, test set of patients identified later in calendar time at the same clinical sites were examined using the same methodology. Using the previously defined cutoff threshold, the test achieved similarly high sensitivity (95%) and specificity (90%), confirming the robustness of the threshold-based assay across both clinical settings and time. This multi-site, temporally distinct validation supports the further development of a nucleic acid-based KS diagnostic test and holds strong potential for improving early KS diagnosis access in high-burden, resource-limited regions.

Indexed as

Herpesvirus 8, HumanMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesSarcoma, KaposiAfrica, EasternBiopsyDNA, ViralHumansSensitivity and SpecificitySkinUgandaDNA, ViraldiagnosticsKaposi sarcomaKSHVLAMPpoint‐of‐care

Identifiers

PMID41439791
PMCPMC12924702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.